颈动脉内膜切除术后因出血再手术的累积风险及出血事件的临床影响
基于VQI颈动脉内膜切除(CEA)模块192,547例手术,构建并验证了预测术后因出血再手术的加权风险评分,识别出包括未使用鱼精蛋白、双联抗血小板等可干预因素;评分≥11者再手术率为3.6%;发生再手术者30天死亡率及其他围术期不良事件显著升高。
要点
- 未使用鱼精蛋白(aOR 2.08)和双联抗血小板(aOR 1.51)是与再手术出血关联最强的可干预因素。
- 风险评分≥11者再手术出血绝对发生率为3.6%,为评分≤0者的600倍。
- 再手术出血患者30天死亡率(OR 1.59)及心梗、心衰、神经事件等风险显著升高。
核心结论
- 开发并验证了预测CEA术后因出血再手术的定量风险评分,最具影响且多可干预的因素包括术中鱼精蛋白使用和避免双联抗血小板治疗。
- 发生再手术出血的CEA患者30天死亡率、心肌梗死、心衰、颅神经损伤、皮肤软组织感染及围术期不良神经事件发生率显著更高。
主要发现
- 与再手术出血显著相关的多变量因素(P<.05):黑人种族(aOR 1.53)、BMI<20 kg/m2(aOR 1.40)、高血压(aOR 1.19)、冠脉血运重建史(aOR 1.16)、充血性心衰(aOR 1.37)、COPD(aOR 1.19)、双联抗血小板(aOR 1.51)、基线抗凝(aOR 1.23)、术前Rankin评分≥2(aOR 1.41)、急诊CEA(aOR 1.36)、外翻式CEA(aOR 1.33)、术者选择放置引流(aOR 1.17)、未使用鱼精蛋白(aOR 2.08)。
- 与再手术出血显著负相关(P<.05):女性(aOR 0.84)、BMI>35 kg/m2(aOR 0.85)、活跃吸烟(aOR 0.85)。
- 风险评分≤0者再手术出血风险仅0.006%;评分≥11者绝对再手术率为3.6%,为评分≤0者的600倍、评分≤5者的3.6倍。
- 内部验证队列各评分点的再手术出血率与主要队列无统计学显著差异。
- 再手术出血患者30天死亡率(OR 1.59)、颅神经损伤(OR 2.03)、围术期神经事件(OR 5.80)、心肌梗死(OR 6.56)、心律失常(OR 4.20)、围术期心衰(OR 5.26)、术后皮肤软组织感染(OR 12.61)均显著升高,P<.001。
临床怎么用
- 可利用该风险评分识别CEA术后因出血再手术高危患者,关注术中鱼精蛋白使用及双联抗血小板等可干预因素。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to identify all preoperative and intraoperative variables in the Vascular Quality Initiative (VQI) carotid endarterectomy (CEA) module that have a statistically significant association with reoperation for bleeding. A weighted risk score was developed and validated to predict this event, with assessment of its impact on 30-day mortality and other adverse perioperative events. METHODS: The VQI CEA module was queried between January 2003 and October 2023. Overall, 192,547 CEA procedures met study inclusion. An internal VQI validation cohort was created with the same exclusion criteria utilizing CEAs performed between November 2023 and October 2024, over which time period 17,449 procedures met inclusion criteria. RESULTS: The following variables had a statistically significant multivariable association (P < .05) with reoperation for bleeding after CEA: Black race (adjusted odds ratio [aOR], 1.53); body mass index <20 kg/m2 (aOR, 1.40); hypertension (aOR, 1.19); history of coronary artery disease revascularization (aOR, 1.16); congestive heart failure (CHF) (aOR, 1.37); chronic obstructive pulmonary disease (aOR, 1.19); dual antiplatelet at time of surgery (aOR, 1.51); on anticoagulation baseline (aOR, 1.23); preoperative Rankin score 2 or higher (aOR, 1.41); urgent/emergent CEA (aOR, 1.36); eversion CEA technique (aOR, 1.33); surgeon selection for drain placement (aOR, 1.17); and lack of protamine utilization intraoperatively (aOR, 2.08). The following variables had a significant (P < .05) protective effect vs reoperation for bleeding after CEA: female sex (aOR, 0.84); body mass index >35 kg/m2 (aOR, 0.85); and active smoking status (aOR, 0.85). Patients with risk scores of zero or less had an only 0.006% risk of return to the operating room for bleeding. There was significant elevation in risk for return to the operating room for bleeding with escalating risk sores. Patients with risk scores 11 and higher had an absolute reoperation for bleeding event rate of 3.6%, which was a total event rate 600 times higher than individuals with scores of 0 or less and 3.6 times as high as individuals with scores as high as 5. The internal VQI validation cohort experienced the event of return to the operating room for bleeding at very similar rates to the primary study source cohort with no statistically significant difference at any of the risk score points, indicating consistency for the risk score. Patients who experienced return to the operating room for bleeding after CEA experienced a statistically significant increased rate of 30-day mortality (OR, 1.59); cranial nerve injury (OR, 2.03); perioperative neurologic event (OR, 5.80); myocardial infarction (OR, 6.56); cardiac dysrhythmia (OR, 4.20); perioperative CHF (OR, 5.26); and skin-soft tissue infection postoperatively (OR, 12.61) with P < .001 for all. CONCLUSIONS: A validated quantitative risk score has been developed to predict reoperation for bleeding after CEA. The most impactful variables, which are also largely modifiable, include intraoperative protamine utilization and avoidance of dual antiplatelet therapy. Patients who experience reoperation for bleeding after CEA experience significantly higher rates of 30-day mortality, myocardial infarction, CHF, cranial nerve injury, skin-soft tissue infection, and adverse perioperative neurologic events.
引用
- Weise L, Darman L, Yirga E, et al. Cumulative risks for reoperation due to bleeding after carotid endarterectomy and the associated clinical impact of bleeding events. J Vasc Surg. 2025. PMID: 40311948. doi:10.1016/j.jvs.2025.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。